艾米·巴勒斯 (Amy Burroughs) 在领导 Cleave Pharmaceuticals 后被任命为 Terns Pharmaceuticals 首席执行官。 Amy Burroughs appointed as Terns Pharmaceuticals CEO after leading Cleave Pharmaceuticals.

拓恩斯制药公司 (Terns Pharmaceuticals) 任命艾米·巴勒斯 (Amy Burroughs) 为其新任首席执行官。 Terns Pharmaceuticals has appointed Amy Burroughs as its new Chief Executive Officer. 此前曾在 Cleave Pharmaceuticals 和 Crinetics Pharmaceuticals 工作的 Burroughs 也将加入 Terns 董事会。 Burroughs, who previously worked at Cleave Pharmaceuticals and Crinetics Pharmaceuticals, will also join Terns' board of directors. 她于2019年4月至2023年10月担任Cleave Pharmaceuticals首席执行官。 She served as the CEO of Cleave Pharmaceuticals from April 2019 to October 2023. 此次任命是继拓恩斯最近在开发小分子候选产品组合以解决肿瘤和肥胖等严重疾病方面取得的成就之后进行的。 This appointment follows Terns' recent achievements in developing a portfolio of small-molecule product candidates to address serious diseases, such as oncology and obesity.